Camp4 Therapeutics (CAMP) closed at $3.96 on October 30, 2026, up 1.5% from the previous close, on volume of 132,155 shares (30-day average 263,085).
Data as of October 30, 2026.
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
CAMP4 lines up an Oct. 20 RNA medicines panel at Chardan’s healthcare conference
Market Chameleon (Wed, 14-Oct 7:48 AM ET)
CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Globe Newswire (Thu, 10-Sep 7:33 AM ET)
Globe Newswire (Tue, 8-Sep 4:05 PM ET)
CAMP4 to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 4:05 PM ET)
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Market Chameleon (Mon, 27-Jul 7:54 AM ET)
CAMP4 Secures $30 Million in New Equity Funding: Institutional Investors Back Therapeutics Expansion
Market Chameleon (Thu, 18-Dec 3:44 AM ET)
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Camp4 Therapeutics trades on the NASDAQ stock market under the symbol CAMP.
As of October 30, 2026, CAMP stock price climbed to $3.96 with 132,155 million shares trading.
CAMP has a beta of 3.10, meaning it tends to be more sensitive to market movements. CAMP has a correlation of 0.10 to the broad based SPY ETF.
CAMP has a market cap of $248.38 million. This is considered a Small Cap stock.
Last quarter Camp4 Therapeutics reported $2 million in Revenue and -$.58 earnings per share. This fell short of revenue expectation by $-3,000 and missed earnings estimates by -$.36.
The top ETF exchange traded funds that CAMP belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CAMP has underperformed the market in the last year with a return of +2.6%, while SPY returned +11.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CAMP shares. However, CAMP has outperformed the market in the last 3 month and 2 week periods, returning +21.1% and +14.8%, while SPY returned +3.9% and -2.1%, respectively. This indicates CAMP has been having a stronger performance recently.
CAMP support price is $3.66 and resistance is $4.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAMP shares will trade within this expected range on the day.
